PPP2R2A insufficiency enhances PD-L1 immune checkpoint blockade efficacy in lung cancer through cGAS-STING activation
Journal of Clinical Investigation · 16.02.2026 · 136 (4)
DOI: 10.1172/jci193354 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 18.12.2025. Verfasst von Zhaojun Qiu und 10 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center and College of Medicine, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Protein Phosphatase 2, Lung Neoplasms, Immune Checkpoint Inhibitors, Nucleotidyltransferases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, National Cancer Center.
Abstract (Originalsprache)
PP2A B55α, a regulatory subunit of protein phosphatase 2 (PP2A), is underexpressed in greater than 40% of non–small cell lung cancer (NSCLC) cases due to loss of heterozygosity of PPP2R2A , the gene encoding this protein. Given that low PPP2R2A expression correlates with poor prognosis, treating PPP2R2A-deficient NSCLC represents an unmet medical need. Here, we show that PPP2R2A knockdown or its heterozygosity ( PPP2R2A +/– ) increases cytosolic DNA, leading to cGAS-STING-type I IFN pathway activation. PPP2R2A deficiency results in elevated expression of immune checkpoint protein PD-L1 via GSK-3β- and STING-dependent mechanisms. PPP2R2A +/– cancer cells have enhanced sensitivity to PD-L1 blockade in a mouse model of lung cancer due to modulation of the tumor immune microenvironment, resulting in increased NK cells and reduced infiltration and function of Tregs. Consequently, PD-L1 antibody treatment increases CD8 + T infiltration and activity, especially in tumors with PPP2R2A heterozygosity. Furthermore, systemic or Treg-specific IFNAR1 blockade reduces the efficacy of PD-L1 blockade in PPP2R2A +/– tumors. Patients with NSCLC with a low PPP2R2A/PD-L1 ratio respond better to immune checkpoint blockade (ICB). These findings underscore the therapeutic potential of ICB in treating PPP2R2A-deficient NSCLC and suggest that PPP2R2A deficiency could serve as a biomarker for guiding ICB-based therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center and College of Medicine, Columbus, Ohio, USA.
- College of Medicine, and.
- The James Comprehensive Cancer Center, Pelotonia Institute for Immuno-Oncology, The Ohio State University, Columbus, Ohio, USA.
- Georgia Cancer Center, Augusta University Medical College, Augusta, Georgia, USA.
- James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
- USF Health, University of South Florida, Tampa, Florida, USA.
Förderung
- NCI NIH HHS
- National Cancer Institute
- National Cancer Center
- U.S. Department of Defense
- nih
Zitieren
APA
Qiu, Z., Song, N. J., Li, A., Singh, D., Prasad, C. B., Yan, C., Carbone, D. P., Wang, Q. E., Zhang, X., Li, Z., & Zhang, J. (2026). PPP2R2A insufficiency enhances PD-L1 immune checkpoint blockade efficacy in lung cancer through cGAS-STING activation. Journal of Clinical Investigation, 136(4). https://doi.org/10.1172/jci193354
Vancouver
Qiu Z, Song NJ, Li A, Singh D, Prasad CB, Yan C, et al. PPP2R2A insufficiency enhances PD-L1 immune checkpoint blockade efficacy in lung cancer through cGAS-STING activation. Journal of Clinical Investigation. 2026;136(4). doi:10.1172/jci193354
BibTeX
@article{Qiu2026,
author = {Qiu, Zhaojun and Song, No-Joon and Li, Anqi and Singh, Deepika and Prasad, Chandra B and Yan, Chunhong and Carbone, David P and Wang, Qi-En and Zhang, Xiaoli and Li, Zihai and Zhang, Junran},
title = {PPP2R2A insufficiency enhances PD-L1 immune checkpoint blockade efficacy in lung cancer through cGAS-STING activation},
journal = {Journal of Clinical Investigation},
year = {2026},
volume = {136},
number = {4},
doi = {10.1172/jci193354}
}
EUVIMED